Healthcare Global Enterprises growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+14.5%+16.3%+12.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+20.3%+17.5%+10.3%
+26.0%+13.3%+14.8%
−53.3%+18.2%+134.5%
−69.6%−7.8%+64.0%
+10.7%+30.9%+16.9%
+42.4%+14.4%−0.5%
+9.5%+11.4%+13.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HCG₹591.45

Healthcare Global Enterprises Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISRAINBOWJLHLCORONAMARKSANSMETROPOLISPARKHOSPSMcap ₹8,511 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+12.8+16.3+14.5—
EBITDA Growth—+10.3+17.5+20.3—
EBIT Growth—+14.8+13.3+26.0—
Net Income Growth—+134.5+18.2-53.3—
EPS Growth—+64.0-7.8-69.6—
Total Assets Growth—+16.9+30.9+10.7—
Total Equity Growth—-0.5+14.4+42.4—
Cash from Operations Growth—+13.1+11.4+9.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.